Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Journal: Cancer Cell
Published: 2020-03-13
DOI: 10.1016/j.ccell.2020.03.001
Affiliations: 18
Go to articleJournal: Cancer Cell
Published: 2020-03-13
DOI: 10.1016/j.ccell.2020.03.001
Affiliations: 18
Go to article